Literature DB >> 11139435

Effect of protease-activated receptor (PAR)-1, -2 and -4-activating peptides, thrombin and trypsin in rat isolated airways.

J M Chow1, J D Moffatt, T M Cocks.   

Abstract

Mechanisms of relaxation and contraction to protease-activated receptor- (PAR) tethered ligand peptides (SFLLRN/TFLLR, SLIGRL and GYPGKF (all C-terminally amidated) for PAR1, PAR2 and PAR4, respectively) and enzymes (thrombin and trypsin) were investigated in isolated segments of rat trachea, main and first order intrapulmonary bronchi. In airway segments previously exposed to SLIGRL, SFLLRN caused contractions that were potentiated by indomethacin, but were independent of mast cell degranulation. Contractions to TFLLR in the intrapulmonary bronchi were similarly potentiated by indomethacin. SLIGRL caused epithelium-dependent relaxations which were unaffected by N(G)-nitro-L-arginine, 1-H-oxodiazol-[1,2,4]-[4,3-a]quinoxaline-1-one or zinc-protoporphyrin-IX but were abolished by haemoglobin in all three regions of the airways. Relaxations to SLIGRL were markedly attenuated by indomethacin only in the main and intrapulmonary bronchi. GYPGKF caused epithelium-dependent relaxations in all three regions of the airway which were only significantly inhibited by indomethacin in the intrapulmonary bronchi. In general, thrombin and trypsin failed to cause any response in the airways tested. Intense PAR2-immunoreactivity was observed on airway epithelium. PAR1-immunoreactivity was faint on airway epithelium and smooth muscle, but was prevalent in mast cells. These findings indicate that PAR2 and possibly PAR4 present on rat airway epithelia mediate smooth muscle relaxation via cyclo-oxygenase-dependent and -independent mechanisms. PAR1-mediated contractions were most likely due to activation of smooth muscle receptors. The general failure of thrombin and trypsin to cause responses which may have been due to endogenous protease inhibitors, highlights the need for caution in assessing pathophysiological roles for PARs if only enzymes are used to activate PARs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11139435      PMCID: PMC1572497          DOI: 10.1038/sj.bjp.0703738

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Proteinase-activated receptor 4 (PAR4): action of PAR4-activating peptides in vascular and gastric tissue and lack of cross-reactivity with PAR1 and PAR2.

Authors:  M D Hollenberg; M Saifeddine; B Al-Ani; Y Gui
Journal:  Can J Physiol Pharmacol       Date:  1999-06       Impact factor: 2.273

Review 2.  The serpin superfamily of proteinase inhibitors: structure, function, and regulation.

Authors:  J Potempa; E Korzus; J Travis
Journal:  J Biol Chem       Date:  1994-06-10       Impact factor: 5.157

3.  Molecular cloning of a potential proteinase activated receptor.

Authors:  S Nystedt; K Emilsson; C Wahlestedt; J Sundelin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

Review 4.  Protease-activated receptors start a family.

Authors:  S R Coughlin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

Review 5.  The structural puzzle of how serpin serine proteinase inhibitors work.

Authors:  H T Wright
Journal:  Bioessays       Date:  1996-06       Impact factor: 4.345

6.  Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.

Authors:  D D Rees; R M Palmer; R Schulz; H F Hodson; S Moncada
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

7.  Ligand cross-reactivity within the protease-activated receptor family.

Authors:  B D Blackhart; K Emilsson; D Nguyen; W Teng; A J Martelli; S Nystedt; J Sundelin; R M Scarborough
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

8.  Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.

Authors:  J Garthwaite; E Southam; C L Boulton; E B Nielsen; K Schmidt; B Mayer
Journal:  Mol Pharmacol       Date:  1995-08       Impact factor: 4.436

9.  Identification of thrombin residues that modulate its interactions with antithrombin III and alpha 1-antitrypsin.

Authors:  B F Le Bonniec; E R Guinto; S R Stone
Journal:  Biochemistry       Date:  1995-09-26       Impact factor: 3.162

10.  Localization and activity of haem oxygenase and functional effects of carbon monoxide in the feline lower oesophageal sphincter.

Authors:  L Ny; P Alm; P Ekström; B Larsson; L Grundemar; K E Andersson
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more
  15 in total

Review 1.  Innate immune responses to environmental allergens.

Authors:  Henk F Kauffman
Journal:  Clin Rev Allergy Immunol       Date:  2006-04       Impact factor: 8.667

Review 2.  Proteinase-activated receptors in the lower urinary tract.

Authors:  James D Moffatt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-10       Impact factor: 3.000

Review 3.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

Review 4.  Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease.

Authors:  M D Hollenberg; K Mihara; D Polley; J Y Suen; A Han; D P Fairlie; R Ramachandran
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

5.  A highly potent agonist to protease-activated receptor-2 reveals apical activation of the airway epithelium resulting in Ca2+-regulated ion conductance.

Authors:  Cara L Sherwood; Michael O Daines; Theodore J Price; Josef Vagner; Scott Boitano
Journal:  Am J Physiol Cell Physiol       Date:  2014-10-15       Impact factor: 4.249

6.  Protease-activated receptor 2 activates airway apical membrane chloride permeability and increases ciliary beating.

Authors:  Derek B McMahon; Alan D Workman; Michael A Kohanski; Ryan M Carey; Jenna R Freund; Benjamin M Hariri; Bei Chen; Laurel J Doghramji; Nithin D Adappa; James N Palmer; David W Kennedy; Robert J Lee
Journal:  FASEB J       Date:  2017-09-05       Impact factor: 5.191

7.  Evidence for the presence of functional protease activated receptor 4 (PAR4) in the rat colon.

Authors:  F Mulè; R Pizzuti; A Capparelli; N Vergnolle
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

8.  Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo.

Authors:  Morley D Hollenberg; Mahmoud Saifeddine; Sabrina Sandhu; Steeve Houle; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

Review 9.  Protease-activated receptors and prostaglandins in inflammatory lung disease.

Authors:  Terence Peters; Peter J Henry
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

10.  RGS4 promotes allergen- and aspirin-associated airway hyperresponsiveness by inhibiting PGE2 biosynthesis.

Authors:  Gordon S Wong; Jamie L Redes; Nariman Balenga; Morgan McCullough; Nathalie Fuentes; Ameya Gokhale; Cynthia Koziol-White; Joseph A Jude; Laura A Madigan; Eunice C Chan; William H Jester; Sabrina Biardel; Nicolas Flamand; Reynold A Panettieri; Kirk M Druey
Journal:  J Allergy Clin Immunol       Date:  2020-03-19       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.